Brief: Histogen And Amerimmune Announce Additional Findings From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients

Histogen

16/08/2021 13:21

Aug 16 (Reuters) - Histogen Inc  HSTO.O :
    * HISTOGEN AND AMERIMMUNE ANNOUNCE ADDITIONAL FINDINGS FROM
ITS
PHASE 1 STUDY OF EMRICASAN IN MILD SYMPTOMATIC COVID-19 PATIENTS
    * HISTOGEN - ADDITIONAL FINDINGS FURTHER REINFORCE THAT
EMRICASAN
CAN POTENTIALLY BE DEVELOPED AS A THERAPEUTIC TREATMENT FOR MILD
TO MODERATE COVID-19

Source text for Eikon:  ID:nGNX6l98b6 
Further company coverage:  HSTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))